Placental cell treatment reverses bone marrow condition

A seven-year-old girl is experiencing a reversal of her aplastic bone marrow after undergoing a placental-based cell treatment. Aplastic bone marrow is a condition where a patient has no blood-forming hematopoietic stem cells in the bone marrow. After months in the hospital and two unsuccessful cell transplants, the girl received two intramuscular injections of PLacental eXpanded (PLX) cells, developed by Pluristem Therapeutics, Inc. Following treatment, the patient’s hematological parameters increased and her general clinical status improved. Subsequent analysis has shown that the treatment worked by stimulating the recovery of the hematopoietic stem cells from the second transplant the patient received. The outcome correlates with the positive effects of PLX on bone marrow in animals. "The results of this unique case indicate that PLX cells may be effective in treating other diseases that affect the bone marrow," Reuven Or, the girl’s physician, said.

Companies
1
Patents
1